StockData

BioCryst Pharmaceuticals vs Krystal Biotech

BCRX and KRYS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCRX and KRYS compare

Krystal Biotech is the larger company, worth 4.6 times as much as BioCryst Pharmaceuticals ($8.8B against $1.9B).

BioCryst Pharmaceuticals grew revenue faster over the last twelve months (68.7% versus 22.6% for Krystal Biotech).

Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 54.8% compared with −40.9% at BioCryst Pharmaceuticals.

Krystal Biotech scores higher on the StockData Score (11 against 9 for BioCryst Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCRXKRYS
Size and price
Market cap$1.9B$8.8B
Share price$7.50$298.55
Change, 1 year5.9%44.8%
Change, 5 years−39.9%650%
Beta (5Y)0.581.01
Employees435295
StockData Score
Total score911 (better)
Valuation score11
Growth score4 (better)1
Performance score23 (better)
Health score26 (better)
Dividend score00
Valuation
P/E–37.4×
P/S2.0× (better)20.1×
P/B–6.5×
EV/EBITDA–40.4×
P/FCF5.1× (better)34.3×
FCF yield19.5% (better)2.9%
Fair value–$195.99
Margin of safety–−52.3%
Growth
Revenue growth (TTM)68.7% (better)22.6%
Revenue growth, 5Y average118%–
Net income growth (TTM)–64.6%
EPS growth (TTM)–62.2%
Profitability
Gross margin97.8%–
Operating margin−33.3%44.9% (better)
Net margin−40.9%54.8% (better)
FCF margin39.7%58.5% (better)
Return on equity–20.1%
Return on invested capital–45.3%
Financial health
Debt / equity–0.00
Interest coverage−4.2×–
Current ratio2.328.32 (better)
Altman Z-score−3.8339.06 (better)
Piotroski F-score7 (better)6
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions103%102%
Held by insiders1.9%17.1%
Insider net buying, 12 months−$4.1M (better)−$105M
Short interest, % of float11.0%12.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.